Approval decision on Yutrepia for PH-ILD expected in January
Amid ongoing litigation, the U.S. Food and Drug Administration (FDA) has agreed to review an application from Liquidia that seeks to extend the approval of Yutrepia — an inhaled dry powder formulation of treprostinil — to cover pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA in 2021…